Information Library

Results for: Enrollment & retention - Clinical Services - Phase II/III

In the complex environment of the New Health, Quintiles is committed to helping you succeed. At every stage of your product’s lifecycle, we are dedicated to delivering real results, being proactive in navigating issues and thinking of new solutions.  Search our library today.

Start Over

  • Sort by:
  • Recently Added
  • Title

  • Energizing Enrollment

    Case Study — October 4, 2011
    The rapid recruitment for this Phase III, open, randomized, controlled, multi-center study in adjuvant triple-negative breast cancer (TNBC) was completed two months earlier than planned.

  • Partnering is Key to Maximizing Rewards in Emerging Markets

    Press Release — September 27, 2011 – While biopharmaceutical spending in emerging markets is growing at double-digit rates – much faster than in developed nations – opportunities in “pharmerging” countries must be balanced with accompanying costs and risks of entering new markets.

  • Malaria Prevention in Sub-Saharan Africa

    Case Study — June 24, 2011
    This study enabled us to be involved in bringing a malaria vaccine to Africa which could substantially reduce an infant mortality rate that currently stands

  • KoNECT & Quintiles Partner to Advance Clinical Research

    Press Release — May 30, 2011 – The Korea National Enterprise for Clinical Trials (KoNECT) and Quintiles have partnered to produce educational events in South Korea for investigators and biopharmaceutical companies.

  • Constant Vigilance

    Case Study — March 16, 2011
    Centralized planning played a key role in improving productivity during site visits and close monitoring ensured the high standards Quintiles put in place were met.

  • Recruiting Trust

    Case Study — March 16, 2011
    Quintiles enrolls 2 cancer trials, 2 times faster than projected

  • Advancing Prevention in Korea

    Case Study — September 14, 2010
    The original recruitment target and timeline were met with more than 1,100 patients screened to yield 420 randomized patients.

  • Managing Trauma

    Case Study — September 14, 2010
    Quintiles overcame the unpredictability of patient recruitment due to the emergency setup and the client was able to file for approval based on phase II data only.

  • QUINTILES AND KAISER PERMANENTE ANNOUNCE ALLIANCE TO ACCELERATE DRUG DEVELOPMENT

    Press Release — May 18, 2010 - Quintiles is accelerating drug development with the addition of Kaiser Permanente's Southern California Permanente Medical Group to its global site program

  • Regulatory Landscapes for Future Antidiabetic Drug Development

    Hear from the Experts — May 12, 2010
    In the March 2010 Journal for Clinical Studies, Dr. Erica Caveney and Dr. Rick Turner analyze the EMA Guidance on diabetes drugs and cardiovascular risk.

Page 1 of 3 (26 results)

Subscribe to Email Based on Your Interests

Set preferences